Effects of Myofacial Release Technique and Sciatic Nerve Slider Technique in Sciatica

July 31, 2024 updated by: Riphah International University

Effects of Myofacial Release Technique With and Without Sciatic Nerve Slider Technique on Pain Range of Motion and Functional Disability Among Cricket Players With Sciatica.

Sciatica is not a medical condition itself, but is a symptom of whatever condition is affecting your sciatic nerve. Pain in the lower back, hip and legs is the most common symptom. However, tingling, numbness and weakness are also symptoms of a damaged sciatic nerve. Physical therapy is a popular and effective way of treating the pain from sciatica. Myofascial release (MFR) is another useful option for sciatica due to the fact that it focuses the connective tissues of the body, including muscles and the fibrous tissues, often called fascia, encircling the joints.This study will be conducted to compare the Effects of myofacial release technique with and without sciatic nerve slider technique on Pain, Range of Motion and Functional Disability among cricket players with Sciatica. This study will be conducted because, no such evidence found in literature to find out the effects of myofacial release technique with sciatic nerve slider technique for sciatica. Myofacial release technique and sciatic nerve slider technique are useful, because these can reduce patients number of visits for the treatment and are easy to use, feasible and cost effective. The sciatic nerve is the largest nerve in the human body. It is formed at the point where five nerves from the lower back all come together, and stretches all the way from the hips to the bottoms of the feet. When this important nerve becomes compressed, inflamed or irritated, it causes the pain in the lower back and legs known as sciatica. A physical therapist uses a number of proven methods to help relieve sciatic pain. One of the most commonly employed methods is known as myofascial release therapy. Myofascial release is a method that a physical therapist can use to treat many sources of pain that are caused by damage to the nervous system. It involves the therapist using hands-on, manual techniques to release areas of tension and pain in the body. Here are three reasons that myofascial release is an effective tool for treating sciatica.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Physical therapy is a popular and effective way of treating the pain from sciatica. Myofascial release (MFR) is another useful option for sciatica due to the fact that it focuses the connective tissues of the body, including muscles and the fibrous tissues, often called fascia, encircling the joints.This study will be conducted to compare the Effects of myofacial release technique with and without sciatic nerve slider technique on Pain, Range of Motion and Functional Disability among cricket players with Sciatica. This study will be conducted because, no such evidence found in literature to find out the effects of myofacial release technique with sciatic nerve slider technique for sciatica. Myofacial release technique and sciatic nerve slider technique are useful, because these can reduce patients number of visits for the treatment and are easy to use, feasible and cost effective. The sciatic nerve is the largest nerve in the human body. It is formed at the point where five nerves from the lower back all come together, and stretches all the way from the hips to the bottoms of the feet. When this important nerve becomes compressed, inflamed or irritated, it causes the pain in the lower back and legs known as sciatica. A physical therapist uses a number of proven methods to help relieve sciatic pain. One of the most commonly employed methods is known as myofascial release therapy. Myofascial release is a method that a physical therapist can use to treat many sources of pain that are caused by damage to the nervous system. It involves the therapist using hands-on, manual techniques to release areas of tension and pain in the body. Here are three reasons that myofascial release is an effective tool for treating sciatica.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
36

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan
        • Recruiting
        • Pakistan sports board
        • Sub-Investigator:
          • Syed Asadullah Arslan, PhD
        • Contact:
          • Yaseen Baloch
          • Phone Number: +923420308930
        • Principal Investigator:
          • Muhammad Mohsin Raza, DPT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age group between 18-35 yrs.
  • Male cricketers
  • Pre diagnosed Patients suffering from sciatica referred from Orthopedic.
  • History of low back pain atleast 03 months before enrollement.
  • Pain while examing when straight leg test (SLR) is performed.
  • Patients who are willing to particiapate in the study

Exclusion Criteria:

  • History of any systemic disease
  • History of trauma
  • History of previous fracture in lower limb.
  • History of prior Surgery
  • Corticosteroid injection for lumber radiculopathy within previous 03 momths;
  • Any known malignancy /neoplasma involved side.
  • Diagnosed/known psychiatric illness.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: MYOFACIAL RELEASE TECHNIQUE, SCIATIC NERVE SLIDER TECHNIQUE
Group A (18) and Group B(18). Both groups will be given a patient evaluation sheet. Group A will receive myofacial release technique and sciatic nerve slider technique with routine physiotherapy. simple myoficial release technique by applying gentle sustained pressure to the myoficial layer for 30-50 seconds. The myofacial release technique will apply on lumber region and calf musle. Group A will receive both techniques
Other: Myofacial release technique and sciatic nerve slider technique
Myofacial release technique, sciatic nerve slider technique 0 week,6 week 12 weeks
Other Names:
  • routine physiotherpy
Other: Myofacial release technique
0week,6 week, 12 weeks
Other Names:
  • Routine physiotherapy
Experimental: MYOFACIAL RELEASE TECHNIQUE
Group B will receive just myofacial release technique and routine physiotherapy. Pain, range of motion and functional disability will be measured before session, immediate effect after first session, then after 06 weeks (18 session) and after weeks 12 (18 session) (3 sessions a week with 7-10 repetitions). with simple myoficial release technique by applying gentle sustained pressure to the myoficial layer for 30-50 seconds. The myofacial release technique will apply on lumber region and calf musle. Group B will receive myofacial release techniqe and routine physiotherapy.
Other: Myofacial release technique and sciatic nerve slider technique
Myofacial release technique, sciatic nerve slider technique 0 week,6 week 12 weeks
Other Names:
  • routine physiotherpy
Other: Myofacial release technique
0week,6 week, 12 weeks
Other Names:
  • Routine physiotherapy

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
range of motion
Time Frame: 0 6 WEEKS 12 WEEKS
will be measured Goniometer
0 6 WEEKS 12 WEEKS
Functional disability
Time Frame: 0 6 WEEKS 12 WEEKS
will be measured LEFS
0 6 WEEKS 12 WEEKS

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Muhammad Mohsin Raza, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 26, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 26, 2024

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 26, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 31, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 31, 2024

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 5, 2024

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 5, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 31, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • REC/RCR&AHS/23/0470

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings